EMA — authorised 8 September 2003
- Application: EMEA/H/C/000481
- Marketing authorisation holder: AbbVie Deutschland GmbH & Co. KG
- Local brand name: Humira
- Indication: Please refer to the product information document.
- Status: approved
🇪🇺 Double-Blind Adalimumab/Placebo + MTX in European Union
EMA authorised Double-Blind Adalimumab/Placebo + MTX on 8 September 2003
Marketing authorisation
Other Immunology approved in European Union
Frequently asked questions
Is Double-Blind Adalimumab/Placebo + MTX approved in European Union?
Yes. EMA authorised it on 8 September 2003.
Who is the marketing authorisation holder for Double-Blind Adalimumab/Placebo + MTX in European Union?
AbbVie Deutschland GmbH & Co. KG holds the EU marketing authorisation.